Söndag 22 December | 07:43:24 Europe / Stockholm

Kalender

Tid*
2025-11-13 07:30 Kvartalsrapport 2025-Q3
2025-08-21 07:30 Kvartalsrapport 2025-Q2
2025-05-06 07:30 Kvartalsrapport 2025-Q1
2025-03-13 N/A Årsstämma
2025-02-19 07:30 Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-03 - Kvartalsrapport 2024-Q1
2024-03-15 - X-dag ordinarie utdelning ALK B 0.00 DKK
2024-03-14 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2023-11-15 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-09 - Kvartalsrapport 2023-Q1
2023-03-20 - X-dag ordinarie utdelning ALK B 0.00 DKK
2023-02-03 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-11 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-03-28 - Split ALK B 1:20
2022-03-17 - X-dag ordinarie utdelning ALK B 0.00 DKK
2022-03-16 - Årsstämma
2022-02-08 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-11 - Kvartalsrapport 2021-Q2
2021-05-05 - Kvartalsrapport 2021-Q1
2021-03-19 - X-dag ordinarie utdelning ALK B 0.00 DKK
2021-03-18 - Årsstämma
2021-02-10 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-08-12 - Kvartalsrapport 2020-Q2
2020-05-06 - Kvartalsrapport 2020-Q1
2020-03-12 - X-dag ordinarie utdelning ALK B 0.00 DKK
2020-03-11 - Årsstämma
2020-02-05 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-13 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-03-14 - X-dag ordinarie utdelning ALK B 0.00 DKK
2019-03-13 - Årsstämma
2019-02-07 - Bokslutskommuniké 2018
2018-11-09 - Kvartalsrapport 2018-Q3
2018-08-15 - Kvartalsrapport 2018-Q2
2018-05-04 - Kvartalsrapport 2018-Q1
2018-03-13 - X-dag ordinarie utdelning ALK B 0.00 DKK
2018-03-12 - Årsstämma
2018-02-06 - Bokslutskommuniké 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-08-16 - Kvartalsrapport 2017-Q2
2017-05-09 - Kvartalsrapport 2017-Q1
2017-03-16 - X-dag ordinarie utdelning ALK B 5.00 DKK
2017-03-15 - Årsstämma
2017-02-07 - Bokslutskommuniké 2016
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-16 - Kvartalsrapport 2016-Q2
2016-05-04 - Kvartalsrapport 2016-Q1
2016-03-11 - X-dag ordinarie utdelning ALK B 5.00 DKK
2016-03-10 - Årsstämma
2016-02-09 - Bokslutskommuniké 2015
2015-11-12 - Kvartalsrapport 2015-Q3
2015-08-18 - Kvartalsrapport 2015-Q2
2015-05-05 - Kvartalsrapport 2015-Q1
2015-03-13 - X-dag ordinarie utdelning ALK B 5.00 DKK
2015-03-12 - Årsstämma
2015-02-09 - Bokslutskommuniké 2014
2014-11-14 - Kvartalsrapport 2014-Q3
2014-08-13 - Kvartalsrapport 2014-Q2
2014-05-08 - Kvartalsrapport 2014-Q1
2014-03-13 - X-dag ordinarie utdelning ALK B 5.00 DKK
2014-03-12 - Årsstämma
2014-02-05 - Bokslutskommuniké 2013
2013-11-08 - Kvartalsrapport 2013-Q3
2013-08-14 - Kvartalsrapport 2013-Q2
2013-05-03 - Kvartalsrapport 2013-Q1
2013-03-13 - X-dag ordinarie utdelning ALK B 5.00 DKK
2013-03-12 - Årsstämma
2013-02-05 - Bokslutskommuniké 2012
2012-11-12 - Kvartalsrapport 2012-Q3
2012-08-16 - Kvartalsrapport 2012-Q2
2012-05-10 - Kvartalsrapport 2012-Q1
2012-03-28 - X-dag ordinarie utdelning ALK B 5.00 DKK
2012-03-27 - Årsstämma
2012-02-22 - Bokslutskommuniké 2011
2011-11-11 - Kvartalsrapport 2011-Q3
2011-08-16 - Kvartalsrapport 2011-Q2
2011-05-10 - Kvartalsrapport 2011-Q1
2011-04-04 - X-dag ordinarie utdelning ALK B 5.00 DKK
2011-04-01 - Årsstämma
2010-03-29 - X-dag ordinarie utdelning ALK B 5.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
AlK-Abelló är verksamt inom läkemedelsbranschen. Bolaget är en utvecklare av allergi- och immunterapi. Verksamhet innehas på global nivå och produkterna säljs både som vaccin och i tablettform. En stor del av verksamheten fokuserar mot forskning och utveckling inom nämnt arbetsområde, där bolaget aktivt arbetar med diagnostisering och behandling av återkommande allergibesvär. Bolaget grundades 1923 och har sitt huvudkontor i Hørsholm, Danmark.
2024-06-21 18:43:00

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the remainder of the year.

  • Revenue is now expected to grow by 12-15% in local currencies (prev.: 10-13%).
  • The EBIT margin is now expected to improve to 18-20% (prev.: 17-19%) vs. 14% in 2023.

The full-year revenue outlook has been upgraded primarily to reflect a continued strong momentum in tablet sales, improved performance for injection- and drop-based allergy immunotherapy products (SCIT/SLIT-drops) as well as an improved pricing outlook in parts of Europe.

The full-year earnings upgrade is driven by the higher sales growth and continued operational leverage. The earnings outlook still includes one-off costs of approximately DKK 60 million related to optimisation efforts as previously communicated. Furthermore, the recent news regarding China (ref Company Announcement 13/2024) does not impact this updated outlook.

Commenting on the revised outlook, CEO Peter Halling said: ”We are pleased to see the continued strong momentum in our core business, as we witness a growing demand for allergy immunotherapy medicines for people with uncontrolled allergies. The guidance upgrade for 2024 is mainly driven by a stronger outlook for European sales across multiple markets.”

ALK will release its Q2 report on 23 August 2024.

ALK-Abelló A/S

For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Forward-looking Statements
This announcement contains forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are naturally subject to risks and uncertainties as various factors, some of which are beyond the control of ALK, may cause actual results and performance to differ materially from the forecasts made in this announcement. Such factors include but are not limited to general economic and business-related conditions, including legal issues, uncertainty relating to demand, pricing, reimbursement rules, regulatory approvals, partners' plans and forecasts, fluctuations in exchange rates, competitive factors and reliance on suppliers. Additional factors include the risks associated with the sourcing and manufacturing of ALK's products. ALK undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.